Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation

British Journal of Pharmacology

Volumn 153, Issue 1, 2008, Pages 50-56

  Mudalagiri, N R ^a   Mocanu, M M ^a   Di Salvo, C ^a   Kolvekar, S ^a   Hayward, M ^a   Yap, J ^a   Keogh, B ^a   Yellon, D M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Caspase 3; Diabetes; Human myocardium; Hypoxia; MAP kinase; PI3K Akt; Reoxygenation; Signal transduction

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; ERYTHROPOIETIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HEART ATRIUM; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; PRIORITY JOURNAL; REOXYGENATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; CASPASE 3; ENZYME ACTIVATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL REPERFUSION INJURY; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 37849034835     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707461     Document Type: Article

References (24)

1. Braunwald E, Kloner RA (1985). Myocardial reperfusion: a double-edged sword? J Clin Invest 76: 1713-1719.
2. Bullard AJ, Govewalla P, Yellon DM (2005). Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100: 397-403.
3. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H et al. (2003). Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108: 79-85.
4. Cai Z, Semenza GL (2004). Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109: 2050-2053.
5. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P et al. (2003). Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802-4806.
6. Deeping R, Kawakami K, Ocker H, Wagner JM, Heringlade M, Noetzold A et al. (2005). Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 130: 877.
7. Efthymiou CA, Mocanu MM, Yellon DM (2005). Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45: 247-252.
8. Hirata A, Minamino T, Asanuma H, Sanada S, Fujita M, Tsukamoto O et al. (2005). Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 19: 33-40.
9. Jegalian AG, Wu H (2002). Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 22: 853-860.
10. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S et al. (2002). Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 99: 10659-10664.
11. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al. (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242.
12. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG et al. (2003). Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 100: 11612-11617.
13. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB et al. (2003). A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007.
14. Rafiee P, Shi Y, Su J, Pritchard Jr KA, Tweddell JS et al. (2005). Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100: 187-197.
15. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S et al. (1998). Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253: 26-32.
16. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M et al. (1998). In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95: 4635-4640.
17. Steiler T, Galuska D, Leng Y, Chilbalin A, Gilbert M, Zierath J (2003). Effect of hyperglycemia on signal transduction in skeletal muscle from Goto-Kakizaki rats. Endocrinology 144: 5259-5267.
18. Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Satoh K et al. (2006). Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 71: 466-477.
19. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L et al. (2003). Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an AKT-dependent pathway. Biochem Biophys Res Commun 308: 990-994.
20. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM (2005). Preconditioning the diabetic heart: the importance of AKT phosphorylation. Diabetes 54: 2360-2364.
21. Ueki K, Kondo T, Kahn CR (2004). Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434-5446.
22. Walker DM, Walker JM, Pugsley WB, Pattison CW, Yellon DM (1995). Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol 27: 1349-1357.
23. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO (2004). Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18: 1031-1033.
24. World Medical Association (1997). Declaration of Helsinki. Cardiovasc Res 35: 2-3.